Veeva Acquires Copli to Automate Life Sciences Content Review

The integration of Copli’s technology into the Veeva ecosystem marks a move to resolve persistent bottlenecks in life sciences content approval. By deploying intelligent agents to verify materials against approved labels and local regulations, the platform shifts the role of human reviewers from manual editors to strategic advisors. This automation is intended to accelerate the time-to-market for critical medical information while maintaining rigorous compliance standards.

Jacob Scheel-Bech, former CEO of Copli, noted that the acquisition provides the necessary scale to transform traditional review workflows. According to Emma Hyland, vice president of Veeva Commercial Content, the tool addresses the long-standing industry challenge of slow review cycles. The company plans to showcase the capabilities of Veeva Falcon MLR during a public webinar scheduled for July 9.